Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tissue Engineering and Cell Transplantation: Technologies, Opportunities, and Evolving Markets

This article was originally published in Start Up

Executive Summary

In 2003, the combined US potential market for tissue-engineering products totaled approximately $58.1 billion. By 2013, the potential market is expected to increase at a compound rate of 4.8%, reaching $92.8 billion, with a number of segments growing at an even faster rate than the market overall.

You may also be interested in...



Scaffolds in Tissue Engineering

Stem-cell-related strategies may predominate these days in tissue engineering, but cell therapy companies know that providing the right microenvironment for nurturing tissue growth remains a difficult and essential challenge. Thus, start-ups remain committed to the developent of cellular matrices that provide the appropriate structure, environment, and bioactivity to encourage tissue growth. The four start-ups profiled in this issue represent a cross-section of strategies.

Clinical Update (03/2007)

Recent clinical developments in the medical device industry, including developments in Artificial Limbs, Tissue-Engineered Therapy for ACL Tears, using Genes to Identify Early Atherosclerosis, and Stem Cell News.

Why Millions from California Won't Get VCs to Fund Stem Cell Start-Ups--But What Will

Despite the millions of dollars from public initiatives, particularly in California, to fund stem-cell research, VCs will still probably stay away until Big Pharma and Big Biotech show more of their own R&D interest in the area.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC090960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel